To investigate the efficacy of aerosolized dornase alfa in improving hypoxia, specifically measured by discharge rates and oxygen saturation levels, in hospitalized patients with acute COVID-19.
Key Findings:
No significant difference in clinical response rate between dornase alfa and placebo groups, indicating limited efficacy.
Secondary outcomes, including mortality and length of hospital stay, were similar across both groups.
Subanalysis by age (<65 or ≥65 years) showed no differences in outcomes.
Interpretation:
Aerosolized dornase alfa did not improve hypoxia in hospitalized patients with acute COVID-19, suggesting limited efficacy in this context.
Limitations:
Study was halted due to the emergence of the Omicron variant, which may have influenced patient outcomes and treatment efficacy.
Results may not be generalizable due to variations in viral strains and vaccination status among participants.
Conclusion:
Inhaled dornase alfa failed to demonstrate clinical benefits in managing hypoxia in severe COVID-19 cases, warranting further investigation in other respiratory infections and contexts.
by Per Åkesson, Lisa Mellhammar, Magnus Rasmussen, Malin Inghammar, Sara Jesperson, Fredrik Månsson, Elin Economou Lundeberg, John Walles, Martin Wallberg, Attila Frigyesi, Adam Linder
Invited narrative review supports early, interprofessional rehabilitation across the ICU recovery continuum while emphasizing heterogeneous evidence and inconsistent implementation worldwide.
